Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Ujjawal H. Gandhi"'
Autor:
Fenghua Qian, Shaneice K. Nettleford, Jiayan Zhou, Brooke E. Arner, Molly A. Hall, Arati Sharma, Charyguly Annageldiyev, Randy M. Rossi, Diwakar B. Tukaramrao, Deborpita Sarkar, Shailaja Hegde, Ujjawal H. Gandhi, Emily R. Finch, Laura Goodfield, Michael D. Quickel, David F. Claxton, Robert F. Paulson, K. Sandeep Prabhu
Publikováno v:
Cell Reports, Vol 42, Iss 7, Pp 112794- (2023)
Summary: Relapse of acute myeloid leukemia (AML) remains a significant concern due to persistent leukemia-initiating stem cells (LICs) that are typically not targeted by most existing therapies. Using a murine AML model, human AML cell lines, and pat
Externí odkaz:
https://doaj.org/article/ce35a814bf814b97aa20a01a202f9e01
Autor:
K. Sandeep Prabhu, Robert F. Paulson, Craig T. Jordan, Mary J. Kennett, Avinash K. Kudva, Emily R. Finch, Shailaja Hegde, Naveen Kaushal, Ujjawal H. Gandhi
PDF file - 772KB, Supplementary Figure 1. Selenium supplementation abrogates leukemia in a Friend leukemia (FVP) model. Supplementary Figure 2. Effect of selenium supplementation on the splenic histopathology in FVP-infected mice. Supplementary Figur
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::309987a607a3b378168c79648b61279e
https://doi.org/10.1158/0008-5472.22404105
https://doi.org/10.1158/0008-5472.22404105
Autor:
Michaela Liedtke, Amarendra K. Neppalli, Elizabeth McGehee, Ehsan Malek, Saad Z. Usmani, Robert F. Cornell, Swapna Narayana, Ankit Kansagra, Natalie S. Callander, Elvira Umyarova, Parameswaran Hari, Arjun Lakshman, Ridhi Gupta, Barry Paul, Joshua Mansour, Zhubin Gahvari, Ujjawal H. Gandhi, William Varnado, Alyssa Barnstead, Saurabh Chhabra, Mark A. Fiala, Emma C. Scott, Megan Jagosky, Saranya Kodali, Ravi Vij, Yubin Kang, Kelly N. Godby, Luciano J. Costa, Shaji Kumar
Publikováno v:
Leukemia. 33:2266-2275
The introduction of CD38-targeting monoclonal antibodies (CD38 MoABs), daratumumab and isatuximab, has significantly impacted the management of patients with multiple myeloma (MM). Outcomes of patients with MM refractory to CD38 MoABs have not been d
Autor:
Amarendra K. Neppalli, Sagar Lonial, Shaji Kumar, Sundar Jagannath, Jatin P. Shah, Mark A. Fiala, Paul G. Richardson, Joshua Mansour, Megan Jagosky, Ujjawal H. Gandhi, Zhubin Gahvari, Yubin Kang, Kelly N. Godby, Michaela Liedtke, Elizabeth McGehee, Ravi Vij, Xiwen Ma, David S. Siegel, Robert F. Cornell, Barry Paul, Ehsan Malek, William Varnado, Ankit Kansagra, Shijie Tang, Luciano J. Costa, Saad Z. Usmani, Emma C. Scott, Arjun Lakshman, Michael Kauffman, Noa Biran, Ridhi Gupta, Saurabh Chhabra, Saranya Kodali, Natalie S. Callander, Elvira Umyarova, Parameswaran Hari, Sharon Shacham, Ajai Chari
Publikováno v:
American Journal of Hematology. 96
Autor:
Amarendra K. Neppalli, Joshua Mansour, Alyssa Barnstead, Ravi Vij, Sharon Shacham, Ehsan Malek, William Varnado, Shijie Tang, Ajai Chari, Megan Jagosky, Xiwen Ma, Shaji Kumar, Saranya Kodali, Saad Z. Usmani, Swapna Narayana, Ridhi Gupta, Jatin P. Shah, Yubin Kang, Emma C. Scott, Kelly N. Godby, Robert F. Cornell, Paul G. Richardson, Ankit Kansagra, Noa Biran, Ujjawal H. Gandhi, Elizabeth McGehee, Sundar Jagannath, David S. Siegel, Natalie S. Callander, Elvira Umyarova, Sagar Lonial, Luciano J. Costa, Michael Kauffman, Zhubin Gahvari, Arjun Lakshman, Mark A. Fiala, Hari Parameswaran, Barry Paul, Saurabh Chhabra, Michaela Liedtke
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 19:e115-e116
Autor:
Mark A. Fiala, Saad Z. Usmani, Jatin J. Shah, Sundar Jagannath, Sagar Lonial, Shijie Tang, Saurabh Chhabra, Yubin Kang, Kelly N. Godby, Luciano J. Costa, Shaji Kumar, Arjun Lakshman, Robert F. Cornell, Paul G. Richardson, Noa Biran, Ehsan Malek, Ajai Chari, David S. Siegel, Michael Kauffman, Xiwen Ma, Amarendra K. Neppalli, Ujjawal H. Gandhi, Sharon Shacham, Natalie S. Callander, Elvira Umyarova, Parameswaran Hari
Publikováno v:
Blood. 134:3125-3125
Introduction: Proteasome inhibitors (PI), immunomodulatory agents (IMiDs) and the CD38 monoclonal antibody daratumumab (dara) have transformed the management of MM, yet eventual refractoriness to these agents seems inevitable. Relapsed and refractory
Autor:
Erkan Baloglu, Dan T. Vogl, Thaddeus J. Unger, Ujjawal H. Gandhi, William Senapedis, Robert F. Cornell, Ajai Chari
Publikováno v:
Clinical lymphoma, myelomaleukemia. 18(5)
Multiple myeloma (MM) is a malignancy of plasma cells that is typically chronic, and relapse is common. Current therapeutic strategies include combination and sequential treatments with corticosteroids, alkylating agents, proteasomal inhibitors, immu
Autor:
Emily R. Finch, Naveen Kaushal, Shailaja Hegde, Robert F. Paulson, Ujjawal H. Gandhi, Avinash K. Kudva, Craig T. Jordan, Mary J. Kennett, K. Sandeep Prabhu
Publikováno v:
Cancer Research. 74:3890-3901
Eradicating cancer stem-like cells (CSC) may be essential to fully eradicate cancer. Metabolic changes in CSC could hold a key to their targeting. Here, we report that the dietary micronutrient selenium can trigger apoptosis of CSC derived from chron
Autor:
Mark A. Fiala, Megan Jagosky, Ravi Vij, Shaji Kumar, Emma C. Scott, Saurabh Chhabra, Saranya Kodali, Ehsan Malek, Arjun Lakshman, Robert F. Cornell, Elizabeth McGehee, Yubin Kang, Ankit Kansagra, Kelly N. Godby, Zhubin Gahvari, Barry Paul, Ridhi Gupta, Natalie S. Callander, Elvira Umyarova, Parameswaran Hari, Luciano J. Costa, Michaela Liedtke, Joshua Mansour, Amarendra K. Neppalli, Alyssa Barnstead, Saad Z. Usmani, Ujjawal H. Gandhi, William Varnado
Publikováno v:
Blood. 132:2015-2015
Introduction Development of anti-CD38 monoclonal antibody therapies (MoABs), including daratumumab and isatuximab, have drastically changed the therapeutic landscape for management of relapsed and/or refractory multiple myeloma (RRMM). However, there
Autor:
Shaji Kumar, Arjun Lakshman, Alyssa Barnstead, Luciano J. Costa, Zhubin Gahvari, Saad Z. Usmani, Ravi Vij, Emma C. Scott, Saranya Kodali, Mark A. Fiala, Megan Jagosky, Ridhi Gupta, Yubin Kang, Kelly N. Godby, Michaela Liedtke, William Varnado, Ehsan Malek, Elizabeth McGehee, Robert F. Cornell, Ankit Kansagra, Joshua Mansour, Ujjawal H. Gandhi, Amarendra K. Neppalli, Natalie S. Callander, Elvira Umyarova, Parameswaran Hari, Saurabh Chhabra, Barry Paul
Publikováno v:
Blood. 132:3233-3233
Introduction Proteasome inhibitors (PIs) and immunomodulatory drugs (IMiDs) have significantly improved survival in patients with multiple myeloma (MM). Refractoriness to PIs and IMiDs results in poor outcomes with a median survival of about 13 month